DaVita (DVA) faced fluctuations in its stock price with a recent pullback, with some seeing this as an opportunity for investors. Barclays cut its price target for DVA and maintained an equal-weight rating. DVA’s stock rating was also lowered by Wall Street Zen, and it hit a new 12-month low. Despite a drop in its stock amid market rises, DaVita is considered a top-ranked growth stock and a top value stock for the long-term. Regulatory concerns and a ransomware threat caused some disturbance but the company continued to provide patient care. Its second-quarter results showed strong earnings and revenues. DVA also announced the offering and pricing of $1 billion Senior Notes. DaVita faced lawsuits from employee benefits plan but managed to navigate challenges through resilience, releasing annual community care reports, and highlighting advancements in chronic disease care. It has aggressive buybacks despite the rising cost of debt. However, it's considered not the best healthcare stock for long-term investment by some. Despite strong Q4 sales, the stock dropped while showing a healthy balance sheet. Many investors in DaVita have seen decent returns of 60% over the past three years.
Davita DVA News Analytics from Thu, 13 Feb 2025 08:00:00 GMT to Sat, 11 Oct 2025 15:39:03 GMT -
Rating 0
- Innovation -1
- Information 7
- Rumor 2
